Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

Metabolic plasticity is an emerging hallmark of cancer, and increased glycolysis is often observed in transformed cells. Small molecule inhibitors that target driver oncogenes can potentially inhibit the glycolytic pathway. Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI) that i...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Matthew J., Eberlein, Cath, Taylor, Molly, Ashton, Susan, Robinson, David, Cross, Darren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349916/
https://www.ncbi.nlm.nih.gov/pubmed/27861144
http://dx.doi.org/10.18632/oncotarget.13388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349916/
https://www.ncbi.nlm.nih.gov/pubmed/27861144
http://dx.doi.org/10.18632/oncotarget.13388

Ejemplares similares